Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06875934
PHASE2

A Trial Comparing SHR-1139 Injection With Placebo in Patients With Moderate-to-severe Plaque Psoriasis

Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd

View on ClinicalTrials.gov

Summary

The objective of this study is to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of SHR-1139 injection in patients with moderate to severe plaque psoriasis.

Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study Evaluating the Efficacy and Safety of SHR-1139 Injection in Patients With Moderate-to-severe Plaque Psoriasis

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

145

Start Date

2025-03-28

Completion Date

2026-10

Last Updated

2025-07-14

Healthy Volunteers

No

Interventions

DRUG

SHR-1139 Injection

SHR-1139 injection.

DRUG

SHR-1139 Injection Placebo

SHR-1139 injection placebo.

Locations (1)

Shanghai Dermatology Hospital

Shanghai, Shanghai Municipality, China